id,filing_uuid,filing_type,registrant_name,registrant_id,client_name,filing_year,filing_period,issue_code,specific_issues,government_entities,income_amount,expense_amount,is_no_activity,is_termination,received_date
3425270,b9db4546-a212-466e-a612-c8e53e143342,3T,ICE MILLER LLP,67854,COALITION FOR RESPONSIBLE COMPOUDING INC.,2025,third_quarter,PHA,Educating Congress and the Executive Branch about compounding procedures and standards.,Food & Drug Administration (FDA),,,0,1,2025-09-03T10:57:52-04:00
3426333,49ae1ef3-97ad-47c8-b55f-16ba088e105e,Q3,TAUZIN STRATEGIC NETWORKS,400786367,RAZORMETRICS,2025,third_quarter,PHA,Lowering Medicare & Medicaid pharmaceutical spend with advanced cost containment systems,"Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",37500,,0,0,2025-09-29T13:22:40-04:00
3426433,086abe74-f210-4408-b65d-0fc758d192b1,Q3,"REPUBLIC CONSULTING, LLC",401016871,IQVIA,2025,third_quarter,PHA,monitor health data policy.,"Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2025-09-30T16:58:34-04:00
3426504,705042af-4b1e-427a-83d1-ad7057c2900a,Q3,PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION,401103605,PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION,2025,third_quarter,PHA,"Discussed issues related to onshoring/friendshoring initiatives, robustness of biopharmaceutical supply chains, drug shortages, and potential impact of tariffs on domestic biopharmaceutical manufacturing.","Bureau of Industry and Security (BIS),Commerce, Dept of (DOC),HOUSE OF REPRESENTATIVES",,50000,0,0,2025-10-01T09:31:32-04:00
3426540,7d6eb167-0413-418d-82f1-b2ba84bc9dd9,3A,PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION,401103605,PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION,2025,third_quarter,PHA,"Discussed issues related to onshoring/friendshoring initiatives, robustness of biopharmaceutical supply chains, drug shortages, and potential impact of tariffs on domestic biopharmaceutical manufacturing.","Bureau of Industry and Security (BIS),Commerce, Dept of (DOC),HOUSE OF REPRESENTATIVES,State, Dept of (DOS)",,50000,0,0,2025-10-01T10:54:16-04:00
3426632,b66dd891-2874-4365-8090-a923b78e3964,Q3,MR. DAN CRIPPEN,401109565,AMGEN,2025,third_quarter,PHA,pharmacy rebates and discounts pharmacy R&D,HOUSE OF REPRESENTATIVES,36000,,0,0,2025-10-01T13:01:52-04:00
3426652,e773778f-a2dc-4737-8e5a-afb3007f7205,Q3,"CORNERSTONE GOVERNMENT AFFAIRS, INC.",75557,CHILDREN'S NATIONAL MEDICAL CENTER,2025,third_quarter,PHA,"Health-related issues including reimbursement, research, public-health & clinical care.","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",50000,,0,0,2025-10-01T13:49:58-04:00
3427050,79c8efc5-ad55-42dd-80d5-67944a4e6193,Q3,AMERICAN PHARMACISTS ASSOCIATION,3071,AMERICAN PHARMACISTS ASSOCIATION,2025,third_quarter,PHA,PBM reform Pharmacist payment reform,"HOUSE OF REPRESENTATIVES,SENATE",,35000,0,0,2025-10-02T13:07:42-04:00
3427236,cbfd2e29-650d-474c-8c1b-971723fa12c3,Q3,MCDERMOTT+ LLC,401103287,ALLIANCE FOR RURAL HOSPITAL ACCESS,2025,third_quarter,PHA,Amendments to Section 340B of the Public Health Service Act regarding eligibility for rural referral centers and sole community hospitals in thefederal discount drug purchasing program.,"HOUSE OF REPRESENTATIVES,SENATE",80000,,0,0,2025-10-03T09:50:39-04:00
3427503,e5453cde-5dd3-41b0-aaca-16b2ffedbbfe,Q3,PENN AVENUE PARTNERS,400918672,"ALKERMES, INC.",2025,third_quarter,PHA,Regulatory and legislative issues impacting Alkermes. Appropriations.,"HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA)",80000,,0,0,2025-10-03T18:27:16-04:00
3427531,10bcefab-3113-4dac-bc28-1328a8c73732,Q3,"GOVERNMENT COUNSEL, LLC",401105070,HEALTHCARE DISTRIBUTION ALLIANCE,2025,third_quarter,PHA,General issues related to pharmaceutical supply chain.,"HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2025-10-03T21:52:37-04:00
3427599,470d056c-60eb-4d92-ab1a-35912a7490b7,Q3,PENN AVENUE PARTNERS,400918672,"UNITEDHEALTH GROUP, INC.",2025,third_quarter,PHA,Pharmacy benefit related issues.,"HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA)",90000,,0,0,2025-10-04T13:17:48-04:00
3427920,9566e4e5-8ae6-47b9-a125-61f2421c6a0b,Q3,"MASON STREET CONSULTING, LLC",401105150,CAPITAL RX INC.,2025,third_quarter,PHA,PBM Reform.,"Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2025-10-06T12:52:14-04:00
3427923,a1b777f8-1ccf-48f5-acce-1382e505d12b,Q3,"MASON STREET CONSULTING, LLC",401105150,DOMPE US INC.,2025,third_quarter,PHA,Tariffs on orphan drugs.,"Commerce, Dept of (DOC),Health & Human Services, Dept of (HHS),White House Office",,,0,0,2025-10-06T12:53:17-04:00
3428273,d95239d5-5640-417c-9cc9-fb2b608b23d6,Q3,AMERICAN COLLEGE OF CLINICAL PHARMACY,57258,AMERICAN COLLEGE OF CLINICAL PHARMACY,2025,third_quarter,PHA,Coverage for direct patient care services of qualified pharmacists under Medicare and other public health programs.,"HOUSE OF REPRESENTATIVES,SENATE",,144981,0,0,2025-10-06T18:11:07-04:00
3428453,9d182b53-c462-4fdb-bc05-1868e658d95f,Q3,THE KPM GROUP DC LLC,401105372,THE HS COALITION,2025,third_quarter,PHA,"S.864, Help Ensure Lower Patient (HELP) Copays Act H. Res 484, Expressing support for the recognition of ""Hidradenitis Suppurativa Awareness Week"" H.R. 5509 Safe Step Act","HOUSE OF REPRESENTATIVES,SENATE",70000,,0,0,2025-10-07T11:08:23-04:00
3428455,867ac50b-e7ae-41ba-ad60-3b86b1c1d844,Q3,THE KPM GROUP DC LLC,401105372,PRAXIS PRECISION MEDICINES,2025,third_quarter,PHA,"H.R.1262/S.932, Give Kids a Chance Act H.R.1509/S.752, Accelerating Kids Access to Care Act","HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2025-10-07T11:10:43-04:00
3428774,fc68ff65-0789-47ec-95fc-6a2c0651cbdf,Q3,THORSEN FRENCH ADVOCACY LLC,400599826,HEALTHCARE DISTRIBUTION ALLIANCE,2025,third_quarter,PHA,Drug Shortages. Issues related to pharmaceutical supply chain. Issues related to government reorganization proposals.,HOUSE OF REPRESENTATIVES,50000,,0,0,2025-10-07T17:20:52-04:00
3428786,d7bf55f9-04c1-4d1c-ad5d-d1ac3dd037fa,Q3,THORSEN FRENCH ADVOCACY LLC,400599826,PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA,2025,third_quarter,PHA,Issues realted to anti-competitive tactics in the pharmaceutical marketplace. S.1040 - Drug Competition Enhancement Act. S.1041 - Affordable Prescriptions for Patients Act.,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2025-10-07T17:33:23-04:00
3428983,74b28dea-aaf8-42e6-9e23-4541c62c26fb,Q3,"PORT SIDE STRATEGIES, LLC",401105394,CENTER FOR HEALTH AND DEMOCRACY,2025,third_quarter,PHA,Issues related to pharmacy benefit managers. H.R.4317 - PBM Reform Act of 2025 - in support. H.R.2484 - Seniors Access to Critical Medications Act of 2025 - opposed. H.R.9096 - Pharmacists Fight Back Act - in support.,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2025-10-08T11:41:28-04:00
3429127,982033cf-a192-4462-a012-51a4d0e33e9a,Q3,UC HEALTH,401103195,UC HEALTH,2025,third_quarter,PHA,340B,"HOUSE OF REPRESENTATIVES,SENATE",,50000,0,0,2025-10-08T14:03:44-04:00
3429569,0d02db6e-7d6e-4642-8c1c-19d6aea6cf4e,Q3,"THE HARPLE GROUP, LLC",401108916,PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION (PILMA),2025,third_quarter,PHA,"Prescription drug industry issues relating to domestic construction and maintenance, and prescription drug pricing Pharmacy Benefit Manager Transparency Act of 2023; Prescription Pricing for the People Act of 2023; HELP Copays Act; Delinking Revenue from Unfair Gouging Act (a/k/a The DRUG Act""); Lowering Drug Costs for American Families Act; Protecting Patients Against PBM Abuses Act; The Drug Act; Lower Costs, More Transparency Act.","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2025-10-09T10:37:23-04:00
3429792,6a5219db-ed3a-41dd-8f29-d796bf4de058,Q3,"KOUNTOUPES DENHAM CARR & REID, LLC",320918,CENCORA INC. (FORMERLY AMERISOURCEBERGEN CORPORATION),2025,third_quarter,PHA,"Issues related to the pharmaceutical supply chain, drug shortages, and national stockpiles.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2025-10-09T14:55:08-04:00
3429819,dc4d3059-6bf0-42df-b548-4f3d23bc2c5f,Q3,"KOUNTOUPES DENHAM CARR & REID, LLC",320918,CONSUMER HEALTHCARE PRODUCTS ASSOCIATION,2025,third_quarter,PHA,General issues related to over-the-counter (OTC) pharmaceutical supply chain.,"HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2025-10-09T15:10:40-04:00
3430028,f6ab13ec-bd05-4896-bc8e-cb4477d15b77,Q3,AEGIS LLC,401108688,"TRIS PHARMA, INC.",2025,third_quarter,PHA,ADHD treatment. Implementation of the Infrastructure Investment and Jobs Act (or bipartisan infrastructure law). Traffic safety (distracted and impaired driving). Issues related to FDA approval. Patient access to non-opioid pain medicines. NO PAIN Act implementation. H.R.1227 / S.475: Alternatives to PAIN Act. Most-Favored Nation (MFN) International reference pricing. Make America Healthy Again (MAHA) Commission.,"HOUSE OF REPRESENTATIVES,Natl Highway Traffic Safety Administration (NHTSA),SENATE",50000,,0,0,2025-10-10T11:21:34-04:00
3430029,4a86e152-8191-4488-9c71-6301fb5e13f7,Q3,AEGIS LLC,401108688,PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA,2025,third_quarter,PHA,"Pharmacy Benefit Manager (PBM) issues and reform. 340B. IRA implementation. H.R.1492: Ensuring Pathways to Innovative Cures (EPIC) Act. Drug pricing. Most-Favored Nation (MFN) International reference pricing. H.R.5378 - Lower Costs, More Transparency Act. H.R.5376 - Share the Savings with Seniors Act. H.R.6283/S.1542 - DRUG Act. H.R.830 - HELP Copays Act.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2025-10-10T11:23:57-04:00
3430150,c7614d38-c2db-441e-b3e2-2287020ae5b7,Q3,CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER,312496,CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER,2025,third_quarter,PHA,340b,"Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",,34890,0,0,2025-10-10T14:41:19-04:00
3430416,cbe53301-60a9-427b-bd87-25847620f26d,Q3,TODD STRATEGY GROUP,401103321,"ASTELLAS PHARMA US, INC.",2025,third_quarter,PHA,Prescription drug pricing.,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2025-10-11T16:18:59-04:00
3430551,fa6b19f2-a9c4-48ac-b3d9-1d9406ffe4fb,Q3,TODD STRATEGY GROUP,401103321,"GENENTECH, INC.",2025,third_quarter,PHA,Prescription drug payment reform. Supply chain. Strategic National Stockpile.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office",60000,,0,0,2025-10-12T13:40:13-04:00
3430580,4dd7c302-a15e-436f-ac49-60d2b8fca7e1,Q3,TODD STRATEGY GROUP,401103321,PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA,2025,third_quarter,PHA,Drug Pricing and Access. Pharmaceutical Supply Chain. Pharmacy Benefit Managers.,"HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2025-10-12T15:38:20-04:00
3430609,ccd92977-98b1-4d5d-aefb-7ac7eaf965c0,Q3,TODD STRATEGY GROUP,401103321,VALISURE,2025,third_quarter,PHA,Drug product quality assurance.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2025-10-12T16:14:15-04:00
3431074,015cd480-ac3f-43b5-a6b4-396c8e8d2a9f,Q3,DAVE KOLBE CONSULTING,401104329,PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION,2025,third_quarter,PHA,"H.R.4317 (PBM Reform Act) - Asking house members to co-sponsor HR 4317 which would ban spread pricing in Medicaid, boost transparency, delinks PBM compensation in Part D, and strengthens CMS oversight of PBM Contracts. H.R. 5256 (Medicare Access to Rural Anesthesiology of 2023) 340B Access Act - Asking house members to co-sponsor 340B Access Act which would make 340B a true safety-net program for patients by ensuring prescriptions are offered to patients at a discount, update and strengthen eligibility requirements, address standards for 340B child sites and subgrantee eligibility.",HOUSE OF REPRESENTATIVES,30000,,0,0,2025-10-13T13:10:34-04:00
3431197,fd543d98-d1b1-4c9c-8702-b95890ddb03f,Q3,E3 STRATEGIC CONSULTING GROUP,401104104,PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION,2025,third_quarter,PHA,"Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing, supply chain issues, pharmacy benefit managers transparency issues, Intellectual property, trade, and employment issues, 340B program, generally; S. 1040, Drug Competition Enhancement Act; H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 4317, PBM Reform Act of 2025; H.R. 5256, 340B ACCESS Act;"" Urged Members and Staff to attend a congressional presentation on US construction jobs in the pharmaceutical industry;",HOUSE OF REPRESENTATIVES,50000,,0,0,2025-10-13T14:35:02-04:00
3431206,d77eb7f8-6c93-4352-978c-63f0cb4c4d0d,Q3,TRUSYNERGY,401107715,BURRELL INTERNATIONAL GROUP LLC (ON BEHALF OF SHIONOGI INC.),2025,third_quarter,PHA,"Funding for the SNS, BARDA, and IBMSC; promoting safer and more effective treatments in the stockpile; promoting onshoring and domestic manufacturing of medicines and their components; prioritizing investments in more effective treatments to combat AMR; PASTEUR Act; reauthorization of the Pandemic and All Hazards Preparedness Act; funding and incentives for MCM development; AMR issues; development of infectious disease and AMR treatments; FY 26 LHHS appropriations; Rare Pediatric Disease Priority Review Voucher","HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2025-10-13T14:43:41-04:00
3431459,4b57ac71-2357-48f1-aea6-589e3d94b89a,Q3,FEROX STRATEGIES,401104769,VIATRIS INC,2025,third_quarter,PHA,Policy and oversight related to the generic pharmaceutical industry. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",70000,,0,0,2025-10-13T20:52:32-04:00
3431742,735bcc4d-53e8-4051-ae9e-5cb5ccedbe65,Q3,THE ALS ASSOCIATION,401104947,THE ALS ASSOCIATION,2025,third_quarter,PHA,H.R.1672 - Maintaining Investment in New Innovation Act - All Provisions H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program - Discussion around encouraging innovation and research transparency for rare disease drugs.,"HOUSE OF REPRESENTATIVES,SENATE",,30000,0,0,2025-10-14T11:04:18-04:00
3431851,cd3703ff-d1d7-448e-930d-3f39854ca39a,Q3,POLSINELLI PC,314911,RESQ PHARMA,2025,third_quarter,PHA,FDA Regulatory Issues,,,,0,0,2025-10-14T11:59:38-04:00
3431899,f967a940-ae9b-4e76-93c4-4fc0ad3f4649,Q3,WAXMAN STRATEGIES,401103693,340B HEALTH,2025,third_quarter,PHA,Issues affecting the 340B drug pricing program; Appropriations for 340B program.,"HOUSE OF REPRESENTATIVES,SENATE",39000,,0,0,2025-10-14T12:23:28-04:00
3432032,21c2f856-1fbc-4d66-8b41-8c22bb079639,Q3,DA VINCI GROUP,11548,"BOESEN & SNOW, LLC",2025,third_quarter,PHA,"Health Care Issues and pharmaceutical-related issues, generally; No Specific legislation during this period.","HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2025-10-14T13:25:23-04:00
3432045,3404ca15-8d11-424d-b7dd-b36e7171ff62,Q3,DA VINCI GROUP,11548,"PROCARE, INC.",2025,third_quarter,PHA,Issues related to PBM reform.,"Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2025-10-14T13:29:42-04:00
3432071,d4d052ae-cf2c-4ce0-b96b-bc3eb05cc7a2,Q3,VERTEX PHARMACEUTICALS INCORPORATED,40027242,VERTEX PHARMACEUTICALS INCORPORATED,2025,third_quarter,PHA,Issues related to the National Defense Authorization Act - access to non-opioids for service members and their families; Issues related to the NDAA S.Amdt.3841 BIOSECURE Act.,"HOUSE OF REPRESENTATIVES,SENATE",,1110000,0,0,2025-10-14T13:41:57-04:00
3432568,57809e38-76c3-4c6f-b5c7-f09bfcad8009,Q3,"KOUNTOUPES DENHAM CARR & REID, LLC",320918,CVS HEALTH,2025,third_quarter,PHA,"Issues related to pharmaceutical supply chains and patient access. Issues related to H.R. 3164, Ensuring Community Access to Pharmacist Services Act and S.2426, Equitable Community Access to Pharmacist Services Act.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2025-10-14T16:15:22-04:00
3432684,911a576e-496f-47e7-a14b-0b5ff8339952,Q3,"KOUNTOUPES DENHAM CARR & REID, LLC",320918,MCKESSON CORPORATION,2025,third_quarter,PHA,"Issues related to H.R. 3164, ensuring Community Access to Pharmacist Services Act. and S.2426, Equitable Community Access to Pharmacist Services Act.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2025-10-14T16:53:24-04:00
3432714,c94a6de7-8195-4bbf-ad74-1b55e9613363,Q3,VENABLE LLP,39941,MEDISCA INC.,2025,third_quarter,PHA,FDA policy; matters related to pharmacy compounding; trade issues related to compounding,,20000,,0,0,2025-10-14T17:12:54-04:00
3432759,f6e3803a-4d5d-49a6-9b6e-6b92f57fe860,Q3,ERIE FAMILY HEALTH CENTERS,401109988,ERIE FAMILY HEALTH CENTERS,2025,third_quarter,PHA,Asked to enact legislation that protects the 340B Drug Pricing Program.,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2025-10-14T17:49:32-04:00
3433037,35a102a2-5c9d-4e9e-ad03-46f4c29ca3a4,Q3,NATIONAL FAMILY PLANNING AND REPRODUCTIVE HEALTH ASSOCIATION,27786,NATIONAL FAMILY PLANNING AND REPRODUCTIVE HEALTH ASSOCIATION,2025,third_quarter,PHA,340B,"Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2025-10-15T08:15:47-04:00
3433187,89b14f12-9b6b-4f5a-ba2a-f1ac1e59fb22,Q3,KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS),401105192,CVS HEALTH,2025,third_quarter,PHA,"Issues encompassing general education regarding the pharmacy benefit manager/pharmacy industry. Issues related to access and affordability of healthcare, prescription drugs, and generic drugs.","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2025-10-15T09:19:52-04:00
3433465,754e167e-faf1-4076-bc47-1dd2e1a5fb7b,Q3,CONSUMER HEALTHCARE PRODUCTS ASSOCIATION,29403,CONSUMER HEALTHCARE PRODUCTS ASSOCIATION,2025,third_quarter,PHA,H.R.4958 - GRAS Act - The Wastewater Infrastructure Pollution Prevention and Environmental Safety (WIPPES) Act - Fluoride and fluoridated water - Additive Ingredients in Drug Products - Over-the-Counter Tests - Pediatric Labeling,"Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,White House Office",254122,,0,0,2025-10-15T10:34:32-04:00
3433875,f6fb5ea0-f6dd-4b0d-abb7-baa121bd4535,Q3,WALGREEN COMPANY,309071,WALGREEN COMPANY,2025,third_quarter,PHA,- H.R.3164: Ensuring Community Access to Pharmacist Services Act: Issues related to access to pharmacist services - H.R. 4317: The PBM Reform Act: Issues related to pharmacy benefit managers - H.R. 2484: Seniors Critical Access to Medications Act; issues related to pharmacist services - Issues related to 340B - Issues related to vaccine access,"HOUSE OF REPRESENTATIVES,SENATE",,620000,0,0,2025-10-15T12:14:09-04:00
3433878,b1f1e351-f90f-4f09-b8e9-d48c3cd01873,Q3,WALGREEN COMPANY,309071,WALGREEN COMPANY,2025,third_quarter,PHA,- H.R.3164: Ensuring Community Access to Pharmacist Services Act: Issues related to access to pharmacist services - H.R. 4317: The PBM Reform Act: Issues related to pharmacy benefit managers - H.R. 2484: Seniors Critical Access to Medications Act; issues related to pharmacist services - Issues related to 340B - Issues related to vaccine access,"HOUSE OF REPRESENTATIVES,SENATE",,620000,0,0,2025-10-15T12:14:14-04:00
3434381,7ebb1961-4d04-4e87-8b8f-dbbb21731b05,Q3,"TARPLIN, DOWNS & YOUNG, LLC",304736,HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.),2025,third_quarter,PHA,Opioid Abuse - General issues related to access to medication assisted treatment General Issues Related to report language regarding paper inserts,"Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office",80000,,0,0,2025-10-15T14:15:16-04:00
3434525,7bfa4749-58f3-4880-9ece-bc893c45dc74,3A,"TARPLIN, DOWNS & YOUNG, LLC",304736,HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.),2025,third_quarter,PHA,Opioid Abuse - General issues related to access to medication assisted treatment General Issues Related to report language regarding paper inserts,"Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office",80000,,0,0,2025-10-15T15:06:04-04:00
3435010,5947f8c4-83ef-46ba-aa70-d620d597e64f,Q3,ARNOLD & PORTER KAYE SCHOLER LLP,4301,"NOVO NORDISK, INC.",2025,third_quarter,PHA,Issues related to the 340B Program. Issues related to general compounding.,"HOUSE OF REPRESENTATIVES,SENATE",80000,,0,0,2025-10-15T17:13:13-04:00
3435199,afebabf8-beff-41a3-a2ea-c191bfc5223c,Q3,"SAREPTA THERAPEUTICS, INC.",401103510,"SAREPTA THERAPEUTICS, INC.",2025,third_quarter,PHA,Issues related to the Inflation Reduction Act's prescription drug provisions,"HOUSE OF REPRESENTATIVES,SENATE",,430000,0,0,2025-10-15T18:45:31-04:00
3435292,688f4c11-85d4-41bf-b6a5-cdfe02c4db71,Q3,HEALTHSPERIEN,401103150,EXACT CARE PHARMACY,2025,third_quarter,PHA,Advocate for inclusion of chronic care pharmacy in CMS and CMMI payment approaches.,"Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2025-10-15T20:52:33-04:00
3435363,8f195b95-1257-4ed9-9e31-736160a8220c,Q3,"DESIMONE CONSULTING, LLC",400931695,PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA),2025,third_quarter,PHA,"Issues related to patient access and pricing. Issues related to policy changes to Medicare Part D. Issues related to 340B reform. Issues related to the EPIC (Ensuring Pathways to Innovative Cures) Act, H.R.1492/S.832. Issues related to Most Favored Nation (MFN) policy. Issues related to PBM reform.","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2025-10-15T22:33:47-04:00
3435572,9b96e251-dc45-4745-968c-400960af9dec,Q3,MR. BRIAN KELLY,40024191,TAKEDA PHARMACEUTICAL COMPANY,2025,third_quarter,PHA,Trade and tariffs,"Commerce, Dept of (DOC),U.S. Trade Representative (USTR),White House Office",10000,,0,0,2025-10-16T09:23:06-04:00
3435780,cd67c160-e3c1-41d9-ac72-6ca6566c57ae,Q3,TRAVERE THERAPEUTICS,401104190,TRAVERE THERAPEUTICS,2025,third_quarter,PHA,"HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals","HOUSE OF REPRESENTATIVES,SENATE",,110000,0,0,2025-10-16T10:12:56-04:00
3435867,805baeef-57e9-4b18-a5a4-4cf2a2023a82,Q3,ELI LILLY AND COMPANY,13392,ELI LILLY AND COMPANY,2025,third_quarter,PHA,"Hospital discounts; 340B program; Prescription drug value, access, quality and compliance with Drug Quality and Safety Act","HOUSE OF REPRESENTATIVES,SENATE",,2345000,0,0,2025-10-16T10:28:56-04:00
3436213,3006f347-2888-4478-8ce3-2bf5343b2ffe,Q3,INDEPENDENT PHARMACY COOPERATIVE,313098,INDEPENDENT PHARMACY COOPERATIVE,2025,third_quarter,PHA,IPC supports Protecting Pharmacies in Medicaid Act (S.927). IPC supports PBM Reform Act of 2025 (HR 4317). IPC supports Patients Before Middlemen Act (S 882). IPC supports The Ensuring Community Access to Pharmacist Services Act of 2025 (ECAPS). CMS Implementation of drug provisions of the IRA 2022-including the drug negotiation provision with changes and prescription drug co-pay spread option. IPC supports the removal of the mandatory NADAC reporting requirement in the OBBB without an adequate and defined corresponding professional dispensing fee. IPC supports the Rural Health Transformation Program.,"Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",,40000,0,0,2025-10-16T11:21:38-04:00
3436225,15b37df3-82ac-47d6-9e9a-f2daf02f5200,Q3,COREWELL HEALTH,298455,COREWELL HEALTH,2025,third_quarter,PHA,340B - Reforms to protect the integrity of the program. PBM Reform/Oversight. Transparency and high costs associated with prescription drugs.,"HOUSE OF REPRESENTATIVES,SENATE",,190000,0,0,2025-10-16T11:24:37-04:00
3436312,9282abcc-79cc-4a1f-a9db-c2f7c9b33559,Q3,"ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)",400762305,"AMERICAN PHARMACIES, INC.",2025,third_quarter,PHA,"Issues related to independent pharmacy, including insurance coverage, network, and reimbursement; S. 526, Pharmacy Benefit Transparency Act; H.R. 2214, Delinking Revenue from Unfair Gouging (DRUG) Act.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2025-10-16T11:40:16-04:00
3436383,f7dfd98e-fe9a-4122-b828-a8eada3d1635,Q3,AMERICAN VETERINARY MEDICAL ASSOCIATION,3630,AMERICAN VETERINARY MEDICAL ASSOCIATION,2025,third_quarter,PHA,"Xylazine; Combating Illicit Xylazine Act (HR1266/S545); Controlled Substances used in veterinary medicine, Controlled Substances Act and regulations as related to veterinary medicine. Issues related to the FDA CVM.","HOUSE OF REPRESENTATIVES,SENATE",,170000,0,0,2025-10-16T11:50:08-04:00
3436541,bbb356f5-f140-4d75-bf95-ca9fc92f9010,Q3,WAKEFERN FOOD CORP.,400588798,WAKEFERN FOOD CORP.,2025,third_quarter,PHA,Protecting Pharmacies In Medicaid Act (S. 927) Patients Before Middlemen Act (S. 882) The PBM Reform Act (H.R. 4317),"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2025-10-16T12:36:45-04:00
3436595,19229165-0ade-4a7c-9abe-c7bebaac58c4,Q3,CAPITOL COUNSEL LLC,313715,"EMD SERONO, INC.",2025,third_quarter,PHA,Issues regarding the availability and pricing of prescription drugs.,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2025-10-16T12:49:53-04:00
3436597,e789a6df-420c-4b8b-8b1e-1a6cff828e72,Q3,CAPITOL COUNSEL LLC,313715,"EMD SERONO, INC.",2025,third_quarter,PHA,Issues regarding the availability and pricing of prescription drugs.,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2025-10-16T12:50:00-04:00
3436719,67888327-ceb1-4fd9-b580-50cd3b9b51e1,Q3,RARE DISEASE COMPANY COALITION,401109501,RARE DISEASE COMPANY COALITION,2025,third_quarter,PHA,HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 1862 - ORPHAN Cures Act HR 1414 - Camerons Law Drug Pricing EO 14297: Most Favored Nation Pricing Proposals,"HOUSE OF REPRESENTATIVES,SENATE",,90000,0,0,2025-10-16T13:17:02-04:00
3436802,a1cb8935-709e-4e79-8e9c-1e82abc52fe3,Q3,BALLARD PARTNERS,401104288,MERCK SHARP & DOHME LLC,2025,third_quarter,PHA,Guidance and advocacy related to drug pricing and tariffs.,,50000,,0,0,2025-10-16T13:29:15-04:00
3437575,dd80ed10-5327-44a7-b734-e89edc1c45c2,Q3,FIERCE GOVERNMENT RELATIONS,401103500,ASSOCIATION OF ACCESSIBLE MEDICINES (FORMERLY KNOWN AS GPHA),2025,third_quarter,PHA,"Supply Chain, Drug Shortages, Tariffs, Patent Thickets, S.1041 - Affordable Prescriptions for Patients Act, S.43 - Skinny Labels - Big Savings Act, S.1302 - A Bill to Provide for Increased Transparency in Generic Drug Applications, S.1954- Biosimilar Red Tape Reduction Act, S.1414 - Expected Access to Biosimilars Act, S.2296 - National Defense Authorization Act for FY 2026, and H.R.3838 - Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026, Generic Drugs","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2025-10-16T15:14:15-04:00
3437685,7632274e-6100-4174-a3b5-6e88c08ab7b2,Q3,"KOUNTOUPES DENHAM CARR & REID, LLC",320918,AMERICAN KRATOM ASSOCIATION,2025,third_quarter,PHA,Issues related to Food and Drug Administration regulatory and consumer access. Issues related to the Federal Kratom Consumer Protection Act.,HOUSE OF REPRESENTATIVES,50000,,0,0,2025-10-16T15:30:36-04:00
3437779,06ff6148-7ad7-4ee0-86bb-71736c09e691,Q3,MASSACHUSETTS MEDICAL SOCIETY,23975,MASSACHUSETTS MEDICAL SOCIETY,2025,third_quarter,PHA,"Prescription Drug Pricing Issues related to prescription drug pricing - no specific bill HR 4002, The Patient Access to Higher Quality Health Care Act","HOUSE OF REPRESENTATIVES,SENATE",,50000,0,0,2025-10-16T15:47:54-04:00
3437806,325e858a-5dc0-440e-a814-f928e34785ec,3T,BLACK DIAMOND STRATEGIES LLC,401104690,"ON DEMAND PHARMACEUTICALS, INC.",2025,third_quarter,PHA,Pharmaceutical manufacturing on demand,"Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,,0,1,2025-10-16T15:52:52-04:00
3437929,1871fdf2-134a-408d-9d2a-97f84a7ab0fc,Q3,DLA PIPER LLP (US),76855,"XEROX HOLDINGS CORPORATION (FORMERLY LEXMARK INTERNATIONAL, INC.)",2025,third_quarter,PHA,"Ensuring full patient access to drug label and package insert information. H.R. 5133, Patients Right to Know Their Medication Act of 2025.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2025-10-16T16:12:11-04:00
3437946,d67a2380-2bd2-4951-b3f2-45d12cfaed63,Q3,HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA),28776,HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA),2025,third_quarter,PHA,Opioid Abuse - General issues related to access to medication assisted treatment General Issues Related to report language regarding paper inserts,"Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",,555348,0,0,2025-10-16T16:14:47-04:00
3438019,b06aa48c-4220-4401-b6cb-95f10234db6e,Q3,DLA PIPER LLP (US),76855,BIOTECHNOLOGY INNOVATION ORGANIZATION,2025,third_quarter,PHA,"340B drug discount program. General issues related to health care. H.R. 946, ORPHAN Cures Act. Issues related to FDA drug review, including PDUFA.","Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2025-10-16T16:24:37-04:00
3438123,e4fb160b-814f-4d54-b0c1-3d7dd3618916,Q3,DLA PIPER LLP (US),76855,CALIFORNIA APARTMENT ASSOCIATION,2025,third_quarter,PHA,Issues regarding the Veterans Health Care Act of 1992.,,80000,,0,0,2025-10-16T16:49:15-04:00
3438251,4d155fcf-46bf-448e-b670-9e317cc85b23,Q3,"BROWNSTEIN HYATT FARBER SCHRECK, LLP",7257,"CENCORA, INC.",2025,third_quarter,PHA,Recognizing pharmacists as providers within Medicare; The Equitable Introduction of Community Access to Pharmacist Services Act Medicare reimbursement.,HOUSE OF REPRESENTATIVES,60000,,0,0,2025-10-16T17:12:07-04:00
3438287,0a7e7f94-6b57-4dab-8370-2b08a7134185,Q3,"KOUNTOUPES DENHAM CARR & REID, LLC",320918,GS1 US,2025,third_quarter,PHA,Issues related to the pharmaceutical supply chain.,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2025-10-16T17:19:50-04:00
3438332,c46a0ea0-52ac-4fe0-b942-d7d59603f1de,Q3,BALLARD PARTNERS,401104288,NATIONAL ASSOCIATION OF CHAIN DRUG STORES,2025,third_quarter,PHA,"Lower healthcare costs, pharmacy coverage and reimbursement issues, (does not include any PBM issues).","Commerce, Dept of (DOC),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office",90000,,0,0,2025-10-16T17:27:19-04:00
3438364,96be73ea-8176-4acb-88bf-1c58efc0820c,Q3,"BROWNSTEIN HYATT FARBER SCHRECK, LLP",7257,WALGREEN CO.,2025,third_quarter,PHA,Issues related to drug pricing reform and transparency Issues related to access and distribution of pharmaceutical products Issues related to Artificial Intelligence in healthcare Issues regarding immunization and vaccines,,50000,,0,0,2025-10-16T17:35:58-04:00
3438394,df1e427c-6442-4e5c-b08a-f42d2b7008bd,Q3,"CASSIDY & ASSOCIATES, INC.",8453,"HIMS & HERS HEALTH, INC. (FORMERLY HIMS, INC)",2025,third_quarter,PHA,Compounding / telehealth / healthcare,"HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2025-10-16T17:50:21-04:00
3438551,b3397ca6-13b0-4a69-9481-d3099e7cba66,Q3,"TAUZIN CONSULTANTS, LLC",400671007,RAZORMETRICS,2025,third_quarter,PHA,Lowering Medicare & Medicaid pharmaceutical spend with advanced cost containment systems.,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2025-10-16T18:35:25-04:00
3438796,4750f1d3-490f-4270-a841-1298a9d565c8,Q3,"BROWNSTEIN HYATT FARBER SCHRECK, LLP",7257,ST SHARED SERVICES LLC DBA KEENOVA THERAPEUTICS,2025,third_quarter,PHA,issues related to pharmaceutical manufacturing Tax and trade policy affecting the pharmaceutical industry,"Commerce, Dept of (DOC),Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE,U.S. Trade Representative (USTR)",80000,,0,0,2025-10-16T23:33:47-04:00
3439189,63138ac6-83ee-4731-8073-33290e58bf29,Q3,BRIGHTSPRING HEALTH SERVICES,401109655,BRIGHTSPRING HEALTH SERVICES,2025,third_quarter,PHA,"Long-term care pharmacy fix, IRA implementation","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE,White House Office",,20000,0,0,2025-10-17T09:13:39-04:00
3439657,71914a70-5f36-4d4a-bcdd-ca3f5d3b1b41,Q3,AMERICAN ACADEMY OF OTOLARYNGOLOGY-HEAD AND NECK SURGERY,1386,AMERICAN ACADEMY OF OTOLARYNGOLOGY-HEAD AND NECK SURGERY,2025,third_quarter,PHA,"H.R.3164, Ensuring Community Access to Pharmacist Services (ECAPS) Act.",HOUSE OF REPRESENTATIVES,,319233,0,0,2025-10-17T10:34:04-04:00
3439721,90e54b11-59c4-476c-b9d7-c4342f402719,3T,ACG ADVOCACY,2057,WALGREEN CO.,2025,third_quarter,PHA,Drug pricing policy issues. Data privacy. Provider status legislation.,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,1,2025-10-17T10:40:48-04:00
3439737,7caaec5c-c2f7-4822-b189-b400a013c7cf,Q3,TRINITY HEALTH,24910,TRINITY HEALTH,2025,third_quarter,PHA,Oppose 340B cuts. HR 4581 340B Patients Act,"HOUSE OF REPRESENTATIVES,SENATE",,240000,0,0,2025-10-17T10:42:24-04:00
3439821,621dd3f6-2c48-4402-a41f-18225db3ba0b,Q3,CHAMBER HILL STRATEGIES,400645947,OS THERAPIES,2025,third_quarter,PHA,cancer immunotherapy and antibody treatment; osteosarcoma,"Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2025-10-17T10:49:30-04:00
3439956,ed62ede6-57cd-4b3d-b911-9212846ce1d6,Q3,"POLARIS GOVERNMENT RELATIONS, LLC",307730,CIGNA CORPORATION,2025,third_quarter,PHA,Drug pricing and issues facing the pharmacy benefit manager industry generally,"HOUSE OF REPRESENTATIVES,SENATE",90000,,0,0,2025-10-17T10:59:14-04:00
3440057,3d33a5e4-1fbf-4b65-8882-eb3af4848fb8,Q3,"BROWNSTEIN HYATT FARBER SCHRECK, LLP",7257,"LILLY USA, LLC",2025,third_quarter,PHA,Issues related to the pharmaceutical industry Issues related to Inflation Reduction Act Implementation Treat and Reduce Obesity Act Pharmaceutical tariffs,SENATE,90000,,0,0,2025-10-17T11:07:22-04:00
3440141,4241abf4-a9aa-4eae-8e7b-65ca36ae5488,Q3,HB STRATEGIES,401104718,BAYER U.S. LLC,2025,third_quarter,PHA,"Provide lobbying support on key issues and track relevant federal policy developments that could impact the pharmaceutical, healthcare industries generally and Bayer specifically.","HOUSE OF REPRESENTATIVES,SENATE",120000,,0,0,2025-10-17T11:12:56-04:00
3440153,d03f2871-81cc-46f6-8140-26b8f0da6755,Q3,HANCE SCARBOROUGH,17443,ALLIANCE FOR PHARMACY COMPOUNDING,2025,third_quarter,PHA,Issues Related to the regulation of pharmacy compounding. Issues related to preserving patient access to compounded medications. Fiscal Year 2026 Appropriations. Drug Shortages,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2025-10-17T11:13:54-04:00
3440171,434ed42b-3e42-4590-b5c2-ae9dbef83981,Q3,HANCE SCARBOROUGH,17443,BOEHRINGER INGELHEIM USA CORPORATION,2025,third_quarter,PHA,"Provide ongoing animal health policy monitoring, assessment, and research support. Telemedicine/telehealth legislation. Farm Bill","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2025-10-17T11:16:15-04:00
3440281,97250792-ba63-41d9-aa3c-ce0fd2d17286,Q3,AARP,1694,AARP,2025,third_quarter,PHA,"H.R. 1, the One Big Beautiful Bill Act of 2025. No bill number. Discussed drug supply chain and Executive Order on strategic reserve of active pharmaceutical ingredients. S. 2620, the Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act of 2025. S. 1784/H.R. 4191, the Mapping America's Pharmaceutical Supply (MAPS) Act of 2025. S.832/H.R. 1492, the Ensuring Pathways to Innovative Cures (EPIC) Act of 2025. No bill number. Discussed the Medicare drug price negotiation program. No bill number. Discussed pharmacy benefit manager reforms. No bill number. Discussed Most Favored Nation drug pricing proposals.","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office",,3810000,0,0,2025-10-17T11:25:59-04:00
3440368,1b9f172e-eae0-4508-9c41-1715cf10c83c,Q3,OMEGA STRATEGIES LLC (DC),401108551,ON DEMAND PHARMACEUTICALS,2025,third_quarter,PHA,"National Defense Authorization Act, H.R. 3838, S. 2296, support for funding of the office of naval research for pharmaceutical and API production.","HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2025-10-17T11:33:17-04:00
3440391,88c94d90-3184-4913-8d49-e5cb0f63ee32,3A,BALLARD PARTNERS,401104288,MERCK SHARP & DOHME LLC,2025,third_quarter,PHA,Guidance and advocacy related to drug pricing and tariffs.,,80000,,0,0,2025-10-17T11:35:17-04:00
3440703,ab651f94-8413-4e9c-8930-aaea5904de89,Q3,BUCHANAN INGERSOLL & ROONEY PC,55291,UNIVERSITY OF PITTSBURGH MEDICAL CENTER,2025,third_quarter,PHA,340B Drug Pricing Program,"HOUSE OF REPRESENTATIVES,SENATE",80000,,0,0,2025-10-17T12:00:18-04:00
3440715,71fa53ae-4554-4ba6-9d03-2242e9063925,Q3,"BCBSM, INC.",5687,BCBSM INC,2025,third_quarter,PHA,"Issues: 340B Program/Transparency; generics access; Pharmacy Benefit Managers; Prescription Drug Cost; Step Therapy Bills: S.1954 - Biosimilar Red Tape Elimination Act To improve the requirements for making a determination of interchangeability of a biological product and its reference product. Sponsor: Sen. Lee, Mike [R-UT] S. 775, Increasing Transparency in Generic Drug Applications To provide for increased transparency in generic drug applications. Sponsor: Sen. Hassan, Margaret Wood [D-NH] H.R.3839 - To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. Sponsor: Rep. Dunn, Neal P. [R-FL-2] S. 1067, Ensuring Timely Access to Generics Act (118th) To amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions. Sponsor: Sen. Shaheen, Jeanne [D-NH] S.1041 - Affordable Prescriptions for Patients Act A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1040 - Drug Competition Enhancement Act A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1096 - Preserve Access to Affordable Generics and Biosimilars Act A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products. Sponsor: Sen. Klobuchar, Amy [D-MN] S.1095 - Stop STALLING Act A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes. Sponsor: Sen. Klobuchar, Amy [D-MN] S.1097 - Interagency Patent Coordination and Improvement Act of 2025 To amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes. Sponsor: Sen. Durbin, Richard J. [D-IL] H.R.4570 - Interagency Patent Coordination and Improvement Act of 2025 To amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes. Sponsor: Rep. Neguse, Joe [D-CO-2] S.2658 - Medication Affordability and Patent Integrity Act To require sponsors of drug applications and holders of approved applications to provide certain submissions and communications to the Food and Drug Administration and the United States Patent and Trademark Office. Sponsor: Sen. Hassan, Margaret Wood [D-NH] S.1302 - Increasing Transparency in Generic Drug Applications Act To provide for increased transparency in generic drug applications. Sponsor: Sen. Hassan, Margaret Wood [D-NH] H.R.1843 - Increasing Transparency in Generic Drug Applications Act To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. Sponsor: Rep. Dunn, Neal P. [R-FL-2]","HOUSE OF REPRESENTATIVES,SENATE",,32000,0,0,2025-10-17T12:02:48-04:00
3440740,6b4281a2-36bf-438a-aee3-be97f95071d2,Q3,"BROWNSTEIN HYATT FARBER SCHRECK, LLP",7257,PIERRE FABRE PHARMACEUTICALS INC.,2025,third_quarter,PHA,"Issues related to drug development, rare disease innovations, and issues impacting the pharmaceutical industry.",,10000,,0,0,2025-10-17T12:04:57-04:00
3440859,2151766f-0d66-48db-97ea-9f94aba2659d,Q3,THE KPM GROUP DC LLC,401105372,"ASTRIA THERAPEUTICS, INC.",2025,third_quarter,PHA,"S.864, Help Ensure Lower Patient (HELP) Copays Act H.R.1509/S.752, Accelerating Kids Access to Care Act H.R.8702/S.4532, Improving Seniors Timely Access to Care Act (118th Congress) H.R.1532/S.822, Scientific External Process for Educated Review of Therapeutics (EXPERT) Act H.R.1262/S.932, Give Kids a Chance Act H.R.1990, American Innovation and R&D Competitiveness Act H.R.1414, Camerons Law","HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2025-10-17T12:17:12-04:00